ILiAD Biotechnologies 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Enrollment open:  CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) -  May 9, 2023   
    P2b,  N=44, Recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | N=600 --> 360 Active, not recruiting --> Recruiting
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Trial completion date, Trial primary completion date:  Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) -  May 3, 2023   
    P2b,  N=600, Recruiting, 
    Active, not recruiting --> Recruiting Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Enrollment closed:  CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) -  May 3, 2023   
    P2b,  N=44, Active, not recruiting, 
    Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024 Recruiting --> Active, not recruiting
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Trial completion date:  CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) -  Mar 9, 2023   
    P2b,  N=44, Recruiting, 
    These results should be confirmed in large phase 3 trials. Trial completion date: Jun 2023 --> Sep 2023
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Trial completion date, Trial primary completion date:  Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) -  Mar 1, 2023   
    P2b,  N=600, Recruiting, 
    Trial completion date: Jun 2023 --> Sep 2023 Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Jan 2024
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
    [VIRTUAL] Serum Bactericidal Activity Induced by Live Attenuated Pertussis Vaccine BPZE1 is Comparable to Boostrix™ () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2040;    
    SBA-Prn correlations were high post-Boostrix, consistent with prior reports showing Prn is the acellular vaccine antigen that mediates SBA. In contrast, BPZE1 bactericidal antibodies appear broader than Prn which may be important given the global rise of Prn-deficient B. pertussis strains.
  • ||||||||||  live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
    Trial completion, Trial completion date:  Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (clinicaltrials.gov) -  Jul 9, 2020   
    P2b,  N=300, Completed, 
    In contrast, BPZE1 bactericidal antibodies appear broader than Prn which may be important given the global rise of Prn-deficient B. pertussis strains. Enrolling by invitation --> Completed | Trial completion date: Oct 2020 --> Jun 2020